Sogen Data · Datasets · 数据专题
肺癌免疫治疗数据集锦
单细胞 · 空间转录组 · bulk · ATAC · 甲基化 · 代谢组 · 蛋白组
本专题承自 Sogen Data 数据整理体系。欢迎加入 Sogen Data 私域群，获取各学科 GEO 数据集整理资料——第二版正在陆续更新，相较第一版的大而全，更加追求实用化与场景化。
人源单细胞
Human · Single-cell
-
01 GSE233203 NSCLC胸水单细胞，免疫联合化疗应答分组
设计对非小细胞肺癌患者胸膜液中的恶性细胞进行单细胞RNA测序，根据组合免疫治疗（atezolizumab plus bevacizumab和carboplatin/paclitaxel）的应答状态划分样本组，比较应答组与非应答组的单细胞转录…
摘要Non-small cell lung cancer patients finally acquire EGFR-TKI resistance. For these patients, combination immunotherapy, atezolizumab plus bevacizumab and carboplatin/paclitaxel (ABCP), was proposed as…
-
02 GSE205335 ICI治疗肺癌多器官单细胞，RECIST应答谱型
设计对接受免疫检查点抑制剂治疗的肺癌患者进行单细胞RNA测序，分析肺、支气管、转移性淋巴结、肝组织及正常肺、正常淋巴结、正常脑组织的肿瘤特征与免疫细胞谱型，比较不同肿瘤阶段（IV、IVA、IIA、IB、ED）、癌症亚型（ADC、SQ、SCL…
摘要We performed single-cell RNA sequencing of lung cancer patients receiving immune checkpoint inhibitors. Tumor signatures and immune cell profiles associated with ICI response were identified in lung c…
-
03 GSE179994 NSCLC抗PD-1前后活检单细胞，Texp克隆动态
设计对36例非小细胞肺癌患者治疗前和治疗期间的肿瘤活检样本（n=47）进行单细胞RNA测序和TCR测序，分析PD-1阻断联合化疗治疗下响应与非响应肿瘤中耗竭T细胞前体（Texp）的动态变化。…
摘要Immune-checkpoint therapies have shown unprecedented clinical success in the treatment of non-small-cell lung cancer, but the underlying mechanisms of anti-PD-1–induced tumour rejection remain incompl…
-
04 GSE167235 NSCLC耗竭CD8 TIL单细胞，关联抗PD耐药
设计对非小细胞肺癌患者的肿瘤浸润淋巴细胞进行单细胞质量流式细胞术和组织成像分析，识别出burned-out样表型的CD8 TIL亚群（Ebo，区别于经典耗竭T细胞），并比较其与Em和Eff亚群在激活标志物表达、凋亡率及IFNg分泌水平的差异…
摘要Tumor-infiltrating lymphocytes (TILs) are considered to be exhausted, lacking proliferative and effector functions, which impairs cancer immunity. We employed single-cell mass cytometry and tissue ima…
-
05 GSE145896 NSCLC TIL单细胞，CD28亚群PD-1阻断应答差异
设计研究对象为非小细胞肺癌患者的肿瘤浸润CD8+ T细胞，采用单细胞RNA测序分析其CD28表达状态。将CD28-PD-1+与CD28+PD-1+CD8+ TILs分组，比较两组细胞在PD-1阻断后的转录特征差异。…
摘要Blockade of programmed death-1 (PD-1) reinvigorates exhausted CD8+ T cells, resulting in tumor regression in cancer patients. Recently, reinvigoration of exhausted CD8+ T cells following PD-1 blockade…
-
06 GSE337519 肺癌新辅助化疗免疫前后配对单细胞
设计对单一肺癌患者肿瘤组织进行新辅助治疗前后的单细胞 RNA 测序，比较治疗前后转录组差异。样本为配对肿瘤组织，无生物重复，治疗方案为三周期联合化疗与免疫治疗，检测方式为单细胞 RNA 测序，分析对象为肿瘤微环境中细胞组成与转录动态。
摘要This study provides a high-resolution single-cell transcriptional profile of lung cancer in the context of neoadjuvant treatment. Utilizing the 10x Genomics platform, we performed single-cell RNA sequ…
-
07 GSE266035 NSCLC治疗前后32周循环T细胞单细胞追踪
设计对同一 NSCLC 患者治疗前及治疗后 4、8、12、24、32 周的循环 T 细胞进行单细胞 RNA 测序与 TCR 测序，采集 PBMC 样本并分选 CD45+CD3+ 细胞，比较治疗前后不同时间点的基因表达及 TCR 序列动态变化。
摘要single-cell RNA/TCR sequencing (scRNA/TCR-seq) of circulating T cells from longitudinally obtained blood samples from the same a patient with NSCLC who had a response and a subsequent progression to a…
-
08 GSE190905 SABR±抗PD-1治疗前后外周血T细胞单细胞
设计对转移性非小细胞肺癌患者外周血中 CD45+CD3+ T 细胞进行单细胞 RNA 测序和 TCR 测序，比较接受立体定向体部放射治疗（SBRT）与接受 SBRT 联合抗 PD-1 治疗（ISBRT）的患者治疗前后 T 细胞表型及 TCR…
摘要Previous studies have demonstrated that stereotactic body radiation therapy (SBRT) could activate systemic immune response, however, these researches showed limitations in comprehensively characterizi…
-
09 GSE213902 NSCLC化疗免疫前后PBMC单细胞，CX3CR1动态
设计对非小细胞肺癌患者治疗前及治疗后3、6、9周的外周血单核细胞进行CD45+CD19-CD3+CD56-细胞分选，采用5' mRNA测序和VDJ测序分析，比较不同时间点的CX3CR1表达水平变化。…
摘要Lack of reliable predictive biomarkers is a major limitation of combination therapy with chemotherapy and anti-PD-1 therapy (chemo-immunotherapy). The increase of peripheral blood (PB) CD8+ T cells ex…
-
10 GSE207422 NSCLC新辅助免疫治疗前后肿瘤单细胞
设计对可切除的非小细胞肺癌（NSCLC）患者在PD-1阻断联合化疗前后的肿瘤微环境进行单细胞RNA测序和bulk RNA测序，比较治疗前后转录组特征的变化。
摘要To address the potential therapy-resistant mechanisms and underly the changes of tumor microenvironment (TME) after immunotherapy, we performed scRNA-seq and bulk RNA-seq from the patients with resec…
-
11 GSE176021 新辅助PD-1治疗后肺癌MANA-T细胞单细胞
设计对接受抗PD-1治疗的肺癌患者肿瘤组织及邻近正常肺组织中的T细胞进行单细胞RNA测序，通过MANAFEST实验识别MANA特异性T细胞克隆并分析其转录特征，比较肿瘤与正常组织中不同抗原特异性T细胞群体的基因表达差异。
摘要Immune checkpoint blockade (ICB) has revolutionized cancer treatment, but most patients do not respond. PD-1 blockade “unleashes” CD8 T cells, including those specific for mutation-associated neoantig…
-
12 GSE303680 肺癌组织块体外PD1-IL2v等四臂处理单细胞
设计使用来自三个肺癌患者的肿瘤碎片（PDTFs），分别接受PD1-IL2v、Isotype-IL2v、anti-PD1（Pembrolizumab-PGLALA）和Isotype对照处理，处理48小时后消化成单细胞悬液，分选CD45⁺CD3…
摘要Antibody-cytokine fusion proteins are being developed as next-generation cancer immunotherapies, aiming to deliver activation signals to targeted immune populations. Among these, PD1-IL2v - an enginee…
-
13 GSE243013 抗PD1+化疗vs纯化疗新辅助NSCLC单细胞图谱
设计对234名新诊断的肺鳞状细胞癌或肺腺癌（无EGFR突变和ALK重排）患者进行新辅助治疗，分为接受抗PD1药物联合铂类化疗双药和仅接受铂类化疗的组别，采集治疗后的肿瘤组织样本，通过单细胞RNA测序和TCR测序分析免疫异质性，比较两组间的差…
摘要Anti-PD(L)1 with chemotherapy is a standard of care for non-small cell lung cancer (NSCLC), but a varying degree of response to the same regimen is observed in patients. The tumor immune microenvironm…
-
14 GSE280232 KRAS/STK11基因型新辅助ICB肺癌单细胞
设计对接受新辅助免疫检查点阻断治疗的可切除KRAS突变非小细胞肺癌患者，按KRASmut/STK11mut和KRASmut/STK11wt基因型分组，采集肺肿瘤组织进行单细胞RNA测序，比较两组肿瘤内T细胞转录特征及临床复发风险差异。
摘要Co-mutations of the KRAS and STK11 genes in advanced non-small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. While neoadjuvant chemoimmunotherapy is now a s…
-
15 GSE317309 CCL21-DC疫苗联合Pembro治疗前后配对取样
设计对23名晚期非小细胞肺癌患者进行CCL21修饰树突状细胞疫苗联合pembrolizumab治疗，采集治疗前及第21、42天的肿瘤活检样本和PBMC样本，进行scRNA/TCR测序，比较治疗前后肿瘤微环境及免疫细胞变化。
摘要Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report results from a phase I trial combining int…
-
16 GSE315510 免疫治疗前后T细胞线粒体电位分型转录组
设计对肺癌患者外周血CD3+ T细胞进行TMRE染色分选为高线粒体膜电位（TMREhigh）和低线粒体膜电位（TMRElow）群体，结合TCRβ测序与单细胞RNA测序分析其基因表达特征。…
摘要Checkpoint inhibitors have transformed cancer treatment, yet predicting responses remains challenging. Mitochondrial quality decreases in tumor infiltrating lymphocytes and correlates with impaired an…
人源空转
Human · Spatial transcriptomics
-
01 GSE329813 新辅助化免NSCLC空间转录组应答亚型
设计新辅助化疗联合免疫治疗的NSCLC肿瘤空间转录组研究，解析免疫微环境异质性并识别与应答相关的分子亚型。
摘要We conduct a single-arm phase 2 trial using pembrolizumab plus platinum-doublet chemotherapy to evaluate the efficacy and safety of perioperative immune-chemotherapy in patients with driver mutation-n…
-
02 GSE271689 NSCLC一线免疫治疗空间多组学预测模型
设计对非小细胞肺癌患者接受一线免疫治疗的肿瘤组织样本进行空间多组学分析，结合Phenocycler Fusion（PCF）对蛋白表达进行单细胞分辨率的空间映射，以及Digital Spatial Profiling（DSP–GeoMx–WT…
摘要Non–small cell lung cancer (NSCLC) has an increasing number of targeted and systemic therapies allowing subsets of patients to achieve long–term durable benefit. Fundamental to understanding responses…
人源bulk
Human · Bulk RNA-seq
-
01 GSE306542 抗PD-1+化疗应答者/非应答者PBMC转录组
-
02 GSE202417 Nivo+贝扎贝特治疗前后配对
设计对晚期非小细胞肺癌患者外周血单核细胞CD8+T细胞进行基因表达分析，采集接受尼伏鲁单抗联合贝扎贝特治疗患者在治疗前与治疗后的配对样本，比较治疗前后转录组差异，同时区分应答者（R）与非应答者（NR）的基因表达特征。
摘要Background. Novel combination therapies with PD-1/PD-L1 inhibitors are needed to overcome resistance to these drugs. Bezafibrate, a ligand of PGC-1a/PPAR complexes, has shown a synergistic antitumor e…
-
03 GSE189045 抗PD-1/PD-L1应答者外泌体miRNA谱
-
04 GSE193049 Nivolumab应答者与非应答者BALF转录组
-
05 GSE111414 PD-1阻断前后PBMC转录组，PR vs PD分组
设计从非小细胞肺癌患者中前瞻性收集治疗前（N1）和治疗4周后（N2）的外周血单核细胞（PBMCs），提取CD8+ T细胞进行bulk RNA测序，比较PD-1阻断治疗前后及临床反应组（部分缓解PR）与原发性进展组（PD）间的转录组差异。
摘要Adaptive immune escape of tumor cells by upregulation of ligands for programmed death 1 (PD-1) has been identified as an important and targetable pathway in many cancer types. Many clinical trials hav…
-
07 GSE136961 抗PD-1治疗前组织免疫基因谱，DCB/NDB
设计对非小细胞肺癌患者接受 anti-PD-1 抗体治疗前的肿瘤组织进行 bulk RNA 测序，采用 Oncomine Immune Response 面板评估 395 个免疫相关基因的表达及肿瘤突变负担，根据临床反应将样本分为持续获益组…
摘要Immune checkpoint blockade is promising for treating non-small-cell lung cancer (NSCLC). We used multipanel markers to predict the response to immune checkpoint inhibitors (ICIs) by characterizing gen…
-
08 GSE225620 新辅助PD-1前后血液转录组与应答标志
设计对31名非小细胞肺癌患者和5名健康供体的血液样本进行RNA测序，比较接受抗PD-1 Tislelizumab联合化疗治疗前后的基因表达差异，分析与治疗反应及总生存率相关的分子和细胞标志物。
摘要The integrated analyses employed in the current study identified blood-based molecular and cellular signatures that are associated with the responsiveness and overall survival of PD-1/PD-L1 blockade t…
-
09 GSE287798 Mock对照vs JQ1处理T细胞ATAC-seq
设计从两位肺癌患者恶性胸腔积液中分离的 CD3+ T 细胞被分为 Mock 处理组与 500 nM JQ1 处理组，在 24-72 小时内接受相应处理后，继续在无药物培养基中培养至第 7 天。…
摘要T cell exhaustion (TEX) represents a critical target for immunotherapy in cancer. Nevertheless, T cells exhibit diminished responsiveness to immune checkpoint inhibitors once they transition to a term…
-
10 GSE115246 抗PD-1治疗应答甲基化预测（多中心）
-
11 GSE287799 JQ1 vs mock处理T细胞RNA/ATAC/代谢联检
设计从三位肺癌患者的恶性胸腔积液中分离CD3+ T细胞，分别用mock和JQ1（500nM）处理三天，于第7天提取总RNA进行RNA-seq，比较处理组与对照组的转录组差异。
摘要T cell exhaustion (TEX) represents a critical target for immunotherapy in cancer. Nevertheless, T cells exhibit diminished responsiveness to immune checkpoint inhibitors once they transition to a term…
-
12 GSE218989 PD-1/PD-L1 治疗肺癌 bulk 队列应答分组
人鼠都有
Human × Mouse
-
01 GSE270148 髓系前体NRF2调控与检查点阻断增益单细胞
设计对小鼠和肺癌患者的骨髓、肺组织、血液及邻近正常肺组织中的髓系前体细胞、循环单核细胞和肿瘤浸润性单核来源巨噬细胞（mo-macs）进行配对转录组和染色质可及性分析，以识别促进肿瘤相关巨噬细胞免疫抑制的髓系前体程序。…
摘要Monocyte-derived macrophages (mo-macs) often drive immunosuppression in the tumour microenvironment (TME) and tumour-enhanced myelopoiesis in the bone marrow fuels these populations. Here we performed…
鼠源单细胞
Mouse · Single-cell
-
01 GSE283827 SCLC小鼠单细胞，aPD-1±ERBB2抑制剂联合
-
02 GSE302517 肺鳞癌小鼠ICB前后应答分组单细胞，Dusp2
设计对肺鳞状细胞癌样本进行单细胞RNA测序，分析免疫检查点阻断治疗前后肿瘤浸润淋巴细胞的转录组变化，按治疗应答分组比较基因型 WT 与 Dusp2−/−小鼠的差异。
摘要Type I interferons (IFN-I) exert context-dependent effects in tumor microenvironment (TME), but their role in shaping immunotherapy response remains unclear. Here, we performed single-cell RNA sequenc…
-
03 GSE275877 Msh2缺失肺肿瘤单细胞，抗PD-1±CTLA-4分组
设计将Msh2敲除的肺肿瘤细胞按Isotype对照、anti-PD-1单抗、anti-PD-1与anti-CTLA-4联合处理分组，通过FACS分离后进行单细胞RNA测序，比较不同治疗组间转录组差异。
摘要Despite the established use of immune checkpoint inhibitors to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and approximately 50% of patients whose tumors…
-
04 GSE165383 ICI前后小鼠CD8亚群TCR测序，CX3CR1标志
设计对小鼠脾脏和肿瘤组织中的CD8+ T细胞亚群（包括CD27loCX3CR1lo、CD27hiCX3CR1lo、CX3CR1hi）及肿瘤浸润淋巴细胞（TILs）进行TCR测序，比较免疫检查点抑制剂（ICI）治疗前后各组细胞的TCR克隆型频…
摘要We investigated the frequency of CX3CR1+CD8+ T cells in peripheral blood (PB) before and during immune checkpoint inhibitor (ICI) therapy, and delineated the TCR repertoire in peripheral CX3CR1+CD8+ T…
-
05 GSE265967 抗生素吸入±抗PD-1肺癌小鼠单细胞/TCR
设计将C57BL/6小鼠分为四组（Saline, Vanco/Neo Aer, Anti-PD-1 antibody, Vanco/Neo Aer + Anti-PD-1 antibody），每组6只，注射2.5×10^5 LLC1细胞后第…
摘要Lungs harbor a resident microbiota, which plays a role in regulating pulmonary immune tolerance. Lung microbiota is modified by the presence of tumor, but the effect of tumor-associated microbiota on …
-
06 GSE335907 KRAS G12C肺癌小鼠sotorasib等处理单细胞
设计对KRASG12C突变小鼠肺癌和结肠癌模型进行单细胞RNA测序，比较不同处理组肿瘤微环境变化。…
摘要KRASG12C inhibitors have demonstrated promising clinical activity in KRASG12C-mutant cancers; however, therapeutic resistance commonly emerges. To investigate the impact of KRASG12 inhibition on the t…
-
07 GSE312357 aAVC治疗vs对照肺癌小鼠单细胞+空转
设计将HPV-E6和E7表达的肺癌细胞（TC-1）接种至小鼠体内，分别设置aAVC治疗组与未治疗对照组。在治疗后第3天和第7天采集肿瘤样本，采用sc-RNA-seq和空间转录组技术分析免疫细胞定位与功能变化。…
摘要Immune evasion by tumors highlights the need to activate both CTLs and NK cells against “immune-desert” type of tumor, yet the synergistic potential of dual activation in immune-desert tumors remains …
-
08 GSE287964 SCLC小鼠Igfbp5 KO±抗PD-1单细胞
设计对小细胞肺癌肿瘤组织进行单细胞 RNA 测序，比较 sgIgfbp5 敲除组与 sgScr 对照组、anti-PD1 治疗组与未治疗组、OSI-906 单独处理组与联合 anti-PD1 治疗组的内皮细胞转录组差异，分析肿瘤细胞内源性 …
摘要Small cell lung cancer (SCLC), a highly aggressive neuroendocrine malignancy, is among the most immune-desert tumor types and exhibits poor response to immunotherapy. However, the mechanisms underlyin…
-
09 GSE285606 miR-29缺失肺癌小鼠IgG治疗模型单细胞
设计使用 KrasG12D;Trp53R172H 基因型的 344SQ_PD1R1 (140P) 细胞系与野生型 344SQ parental (WT) 细胞系，分别进行 IgG 抗体治疗（每周腹腔注射 200ug/mouse），在 4 周…
摘要Immune checkpoint inhibitors (ICI), like those that block PD-1/PD-L1, have revolutionized oncological therapy for patients with non-small cell lung cancer (NSCLC). However, most patients demonstrate n…
-
10 GSE288231 表观+BCL-XL抑制剂联合抗PD-1小鼠单细胞
设计对Lewis肺癌小鼠肿瘤的免疫细胞进行单细胞RNA测序，比较vehicle组与CM272联合anti-PD-1、anti-Bcl-XL联合anti-PD-1、CM272联合anti-Bcl-XL及三联治疗组的基因表达差异。
摘要We have used a single-cell sequencing approach to study the changes induced in the immune cells present in the tumor microenvironment of Lewis lung cancer (LLC) mouse tumors treated with a novel thera…
-
11 GSE268555 免疫沙漠肺癌DDX54 KD±抗PD-1单细胞
设计对免疫沙漠型肺癌的异种移植瘤组织中分离的CD45阳性免疫细胞进行单细胞RNA测序，比较抗PD1处理组（PD1）与未处理对照组（CTRL）的基因表达差异，以评估DDX54敲低对免疫细胞浸润和抗PD1治疗敏感性的影响。
摘要High tumor mutational burden (TMB) is a predictive biomarker for the responsiveness of cancer to immune checkpoint inhibitor therapy that indicates whether immune cells can sufficiently recognize canc…
-
12 GSE289959 微波瘤源微粒处理肺癌小鼠单细胞
设计将LLC细胞悬液接种于C57BL/6小鼠皮下肿瘤组织，待肿瘤形成后随机分为MW-TMPs组、UV-TMPs组和PBS对照组，每组n=6。通过微波辐射制备MW-TMPs，紫外辐射制备UV-TMPs，PBS作为阴性对照。…
摘要Tumor-derived microparticles (TMPs), a subtype of extracellular vesicles, hold great promise in tumor immunotherapies and vaccines, and have demonstrated significant potential as drug delivery systems…
-
13 GSE222158 CCL21-DC疫苗±抗PD-1肺癌小鼠单细胞
设计对肺癌小鼠模型肺组织中的免疫细胞进行单细胞转录组测序，比较不同治疗组（对照组、IT CCL21-DC治疗组、IP anti-PD-1抗体治疗组及联合治疗组）的基因表达差异。
摘要We used in situ vaccination with autologous dendritic cell secreting CCL21, in combination with immune checkpoint inhibitor, anti-PD-1, to treat oncogene-driven non-small cell lung cancer in a murine …
-
14 GSE249002 Romidepsin±抗PD-1小鼠肿瘤单细胞
设计对肺癌免疫治疗相关的小鼠肿瘤模型进行单细胞RNA测序，比较对照组、PD1治疗组、Romidepsin处理组及PD1联合Romidepsin处理组的基因表达差异。
摘要Epigenetic regulation plays a crucial role in the development and progression of cancer, including the regulation of antitumor immunity. The reversible nature of epigenetic modifications offers potent…
-
15 GSE282715 aPD-1+ERBB2抑制剂联合处理PBMC单细胞谱
设计小鼠SCLC模型PBMC T细胞经vehicle与anti-PD-1联合ERBB2抑制剂处理，10x单细胞RNA测序（含TCR文库），比较免疫调控相关转录差异。
摘要Small cell lung cancer (SCLC) represents ~15% of all lung cancers and is characterized by its highly aggressive phenotype and its dismal outcome. Though the addition of immune checkpoint blockade to c…
鼠源空转
Mouse · Spatial transcriptomics
-
01 GSE291687 sotorasib+anti-CD47联合处理肺癌空转
设计将LLC Nras KO syngeneic肺肿瘤分为vehicle、sotorasib（100mg/kg）、anti-CD47（100μg/body）及组合治疗组，各组接受对应处理后进行空间转录组分析，比较不同处理条件下肿瘤组织的基因…
摘要Although KRAS G12C inhibitors have altered the treatment strategy of patients with KRAS G12C mutant lung cancer, their efficacy is insufficient to eliminate tumors. Here, we identified that inhibition…
-
02 GSE285341 DDX54 KD增强抗PD-1肺癌小鼠空转
-
03 GSE261890 NSCLC小鼠空转，免疫治疗敏感vs耐药屏障
设计对非小细胞肺癌（NSCLC）小鼠模型进行空间RNA测序，比较免疫治疗敏感组（含抗PD1治疗和安慰剂）与耐药组（含抗PD1治疗和安慰剂）在肿瘤细胞胶原蛋白表达及物理屏障形成方面的差异。
摘要Drug resistance is the principal challenge of cancer therapies, including recently developed immunotherapy. More and more popular use of immunotherapy, especially treatments with immune checkpoint inh…
鼠源bulk
Mouse · Bulk RNA-seq
-
01 GSE246922 ICB复发vs亲代肺癌小鼠癌细胞转录组
设计对两种小鼠肺癌模型（LLC1和KP）的CD45-癌细胞进行bulk RNA-seq，包含父代、慢性低剂量IFNG处理及免疫检查点阻断（ICB）复发三个条件，每个条件设3个生物重复。…
摘要Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC …
-
02 GSE309199 Entinostat±抗PD-1处理小鼠SCLC转录组
设计将Rb1/Trp53/MycT58A (RPM)小鼠肺肿瘤组织与正常肺组织进行RNA-seq分析，比较vehicle、entinostat单药、anti-PD-1单药及联合治疗组的基因表达差异。…
摘要Small Cell Lung Cancer (SCLC) is a highly aggressive malignancy, accounting for approximately 15% of all lung cancer cases. Characterized by low immunogenicity, SCLC may utilize epigenetic mechanisms …
-
03 GSE298051 TNG260±抗PD-1 STK11缺失小鼠RNA/ChIP
设计将STK11缺失的KL和KP肺癌细胞系分别接种于雌性及雄性小鼠右 flank，形成皮下肿瘤模型。小鼠被随机分为六组，分别接受DMSO对照、TNG260单药、TNG260联合anti-PD-1抗体治疗。…
摘要Non-small cell lung cancer (NSCLC) patients with loss of the tumor suppressor gene STK11 are resistant to immune checkpoint therapies like anti-PD-1. Our in vivo CRISPR screen identified HDAC1 as a ta…
-
04 GSE293295 DGK抑制剂±抗PD-1小鼠肿瘤转录组
设计将MC38肿瘤细胞植入雌性C57BL/6小鼠体内，待肿瘤体积达~100 mm3后随机分入抗PD-1治疗组、BMS-986408单药组、抗PD-1/BMS-986408联合治疗组及溶剂对照组（每组5只），治疗7天后收集肿瘤组织进行bulk…
摘要DGKα and DGKζ are lipid kinases that negatively regulate T cell signaling through diacylglycerol (DAG) metabolism, making them attractive targets for next-generation immunotherapy. Here, we disclose t…
-
05 GSE263386 放疗±免疫检查点抑制肺癌小鼠RNA-seq
设计对LLC1-sgLkb1和LLC1小鼠肿瘤样本分别采用辐射、免疫检查点抑制剂或联合治疗，每组3个重复，进行RNA测序，比较不同处理条件下肿瘤组织的基因表达差异。
摘要Despite accumulating cases of radiotherapy-induced abscopal effect in the lung cancer with the introduction of immune checkpoint inhibitors (ICIs), the occurrence of this effect remains infrequent and…
-
06 GSE239485 Poly I:C/抗PD-1/C5aR1三联小鼠转录组
设计将Lewis Lung Cancer肿瘤组织分为vehicle组、poly I:C和anti-PD-1联合处理组、poly I:C、anti-PD-1和anti-C5aR1三联处理组，采用RNA-Seq检测总RNA的基因表达，比较三组间…
摘要In syngeneic solid tumor models, C5aR1 inhibition significantly enhanced the effectiveness of poly I:C, a toll-like receptor 3 (TLR3) agonist, combined with Programmed cell death protein 1 (PD-1)/Prog…
-
07 GSE225163 CCL7+Flt3L±抗PD-1小鼠CD8 T转录组
设计对KrasLSL-G12D/+Tp53fl/fl非小细胞肺癌小鼠肺组织中分选的常规型1树突状细胞（cDC1s）进行RNA测序，比较PBS、PD-1Ab、PD-1Ab7及Flt3L联合PD-1Ab7处理组的基因表达差异。
摘要Immune checkpoint inhibitors (ICIs) represented by anti-PD-1/PD-L1 antibodies have been widely applied for various cancers and the response rate to ICIs is closely associated with the tumor immune mic…
-
08 GSE225126 CCL7+Flt3L±抗PD-1小鼠cDC1转录组
设计对携带肿瘤的肺组织中分选的cDC1细胞进行RNA-seq，比较接受PBS、PD-1Ab、PD-1Ab7及Flt3L联合PD-1Ab7处理的KrasLSL-G12D/+Tp53fl/fl NSCLC小鼠的基因表达差异。
摘要Immune checkpoint inhibitors (ICIs) represented by anti-PD-1/PD-L1 antibodies have been widely applied for various cancers and the response rate to ICIs is closely associated with the tumor immune mic…
-
09 GSE210547 H460裸鼠抗PD-1治疗vs盐水芯片转录组
设计将8-9周龄雌性裸鼠分为治疗组和对照组，注射NCI-H460细胞后，治疗组每周两次接受抗PD-1抗体治疗，对照组接受生理盐水，通过微阵列分析肿瘤组织的基因表达，比较治疗与对照组的差异。
摘要Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 axis have made a breakthrough in the treatment of non-small cell lung cancer (NSCLC). However, a paradoxical boost in tumor growth was reported…
-
10 GSE182228 Palbociclib±抗PD-1 LKB1缺陷小鼠RNA
设计对LKB1缺陷型肺腺癌小鼠肿瘤样本分别给予Vehicle、Palbociclib、anti-PD-1抗体或其组合处理，每组3个重复，采集组织进行RNA-Seq测序，比较不同处理组间肿瘤免疫微环境的转录组差异。
摘要LKB1 deficiency in lung adenocarcinoma (LUAD) leads to primary resistance to immune checkpoint inhibitors. However, the underlying molecular mechanism remains unclear. Here, we showed that LKB1 defici…
-
11 GSE261597 胶原屏障免疫治疗获得性耐药ATAC图谱
设计表达胶原的肿瘤细胞构建物理屏障介导NSCLC免疫治疗获得性耐药，以ATAC-seq解析耐药与敏感模型的染色质状态差异。
摘要Drug resistance is the principal challenge of cancer therapies, including recently developed immunotherapy. More and more popular use of immunotherapy, especially treatments with immune checkpoint inh…
-
12 GSE309213 Entinostat±抗PD-1 RPM小鼠ATAC-seq
设计对Rb1/Trp53/MycT58A (RPM)小鼠模型肺肿瘤组织与正常肺组织进行ATAC-seq分析，比较vehicle组、entinostat单用组、anti-PD-1单用组及组合治疗组的表观遗传差异。…
摘要Small Cell Lung Cancer (SCLC) is a highly aggressive malignancy, accounting for approximately 15% of all lung cancer cases. Characterized by low immunogenicity, SCLC may utilize epigenetic mechanisms …
-
13 GSE285215 PD-1敏感vs耐药肿瘤细胞处理对照多组学
设计对肺腺癌小鼠模型的肿瘤组织进行RNA表达分析，比较PD1敏感型（Sen）与PD1耐药型（Res）肿瘤细胞在anti-PD-1处理与对照IgG处理下的基因表达差异。…
摘要Cancer creates an immunosuppressive environment that hampers immune responses, allowing tumors to grow and resist therapy. One way the immune system fights back is by inducing ferroptosis, a type of c…
-
14 GSE216675 PKM2 WT/KO CD8 T共转输bulk±抗PD-1
设计将PKM2野生型和敲除型OT-I+ Thy1.1+ CD8+ T细胞按Thy1.1 zygosity分组，共转移至荷HKP1-ova-GFP肺肿瘤的Thy1.2+/+ C57BL/6小鼠，随后分别给予IgG或anti-PD-1处理。…
摘要In this study we investigated how manipulation of the glycolytic enzyme pyruvate kinase muscle 2 (PKM2) alters CD8+ T cell gene expression and responsiveness to PD-1 checkpoint blockade in orthotopic …
-
15 GSE310740 cJun-ROR1 CAR-T输注后分选bulk
设计对KP-ROR1肺癌肿瘤小鼠注射ROR1或cJun.ROR1 CAR-T细胞后5天，采集肺组织进行bulk RNA-seq，比较不同CAR-T细胞类型与vehicle或aPD-L1处理组的转录组差异。
摘要CAR-T therapy has shown limited synergy with PD-1/PD-L1 blockade, but the mechanisms underlying resistance remain unclear. PD-1⁺TCF1⁺ stem-like T cells mediate responses to PD-1/PD-L1 blockade and are…
边缘条目（单列）
Borderline · 免疫治疗直接性较弱，单列备查
-
01 GSE224216 hMENA剪接调控ICB耐药的ATAC与转录组
设计将人类非小细胞肺癌 H2030 细胞系按 3 个独立重复分组，分别转染非靶向 RNA 池、hMENA11a siRNA 池和 hMENA(t) siRNA 池，提取总 RNA 并进行 RNA-Seq 测序，同时结合 ATAC-Seq、流…
摘要Understanding how cancer signaling pathways promote an immunosuppressive program which sustains acquired or primary resistance to immune checkpoint blockade (ICB) is a crucial step in improving immuno…
-
03 GSE154993 BMP7介导抗PD-1耐药的RRBS甲基化
课题合作 · 扫码加微信
bioinformaticsboy